$LSTA Balance Sheet | Understand Stock

$LSTA

$1.06 +$0.06 (6.44%) Close

$LSTA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q2 FY2025 As of Jun 30, 2026	Q1 FY2025 As of Mar 31, 2026	Q4 FY2024 As of Dec 31, 2025	Q3 FY2024 As of Sep 30, 2025	Q2 FY2024 As of Jun 30, 2025	Q1 FY2024 As of Mar 31, 2025	Q4 FY2023 As of Dec 31, 2024	Q3 FY2023 As of Sep 30, 2024	Q2 FY2023 As of Jun 30, 2024	Q1 FY2023 As of Mar 31, 2024	Q4 FY2022 As of Dec 31, 2023	Q3 FY2022 As of Sep 30, 2023	Q2 FY2022 As of Jun 30, 2023	Q1 FY2022 As of Mar 31, 2023	Q4 FY2021 As of Dec 31, 2022	Q3 FY2021 As of Sep 30, 2022	Q2 FY2021 As of Jun 30, 2022	Q1 FY2021 As of Mar 31, 2022	Q4 FY2020 As of Dec 31, 2021	Q3 FY2020 As of Sep 30, 2021
ASSETS
Cash and cash equivalents
Marketable securities
Accounts receivable
Prepaid and other current assets
Total current assets
Property and equipment, net
Other Investments
Acquired license-intangible, net
Other assets
Total assets

LIABILITIES, NON-CONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY
Liabilities
Accounts payable
Accrued liabilities
Total current liabilities
Other long-term liabilities
Total liabilities
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.000067 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2023 and December 31, 2022, respectively
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 9,119,742 and 8,834,613 shares at June 30, 2026 and December 31, 2025, respectively; and outstanding, 9,119,004 and 8,833,875 shares at June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Treasury stock, at cost; 738 shares at June 30, 2026 and December 31, 2025
Accumulated deficit
Accumulated other comprehensive loss
Total Lisata Therapeutics, Inc. stockholders' equity
Non-controlling interests
Total equity

Total liabilities, non-controlling interests and stockholders' equity

Comments